Vaccinex, Inc. (VCNX)
NASDAQ: VCNX · IEX Real-Time Price · USD
7.10
-0.63 (-8.15%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Vaccinex Revenue
Vaccinex had revenue of $124.00K in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $104.00K. In the year 2023, Vaccinex had annual revenue of $570.00K with 107.27% growth.
Revenue (ttm)
$124.00K
Revenue Growth
-84.97%
P/S Ratio
90.71
Revenue / Employee
$3,100
Employees
40
Market Cap
11.25M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 570.00K | 295.00K | 107.27% |
| Dec 31, 2022 | 275.00K | -625.00K | -69.44% |
| Dec 31, 2021 | 900.00K | 275.00K | 44.00% |
| Dec 31, 2020 | 625.00K | 102.00K | 19.50% |
| Dec 31, 2019 | 523.00K | -201.00K | -27.76% |
| Dec 31, 2018 | 724.00K | 634.00K | 704.44% |
| Dec 31, 2017 | 90.00K | -226.00K | -71.52% |
| Dec 31, 2016 | 316.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RedHill Biopharma | 6.53M |
| Senti Biosciences | 1.28M |
| Traws Pharma | 226.00K |
| BioRestorative Therapies | 149.50K |
| Cardio Diagnostics Holdings | 32.99K |
VCNX News
- 6 weeks ago - Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease - GlobeNewsWire
- 2 months ago - Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Vaccinex Reports 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 5 months ago - Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology - GlobeNewsWire
- 5 months ago - Vaccinex, Inc. Announces Reverse Stock Split - GlobeNewsWire
- 5 months ago - Vaccinex Announces Pricing of $3.7 Million PIPE Financing - GlobeNewsWire
- 8 months ago - Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule - GlobeNewsWire